Actively Recruiting
Open-Label Study of a Single Dose of HRS-4729 Injection in Healthy Adults and Patients With Varying Renal Impairment
Led by Fujian Shengdi Pharmaceutical Co., Ltd. · Updated on 2026-09-16
32
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetic effects of a single dose of HRS-4729 injection in adults aged 18 to 65 years with varying levels of kidney function, including mild, moderate, and severe renal impairment, as well as in healthy participants. The study is a Phase 1, open-label, parallel-group trial designed to understand how kidney health affects the bodys processing of HRS-4729. Participants are divided into four groups healthy individuals with normal kidney function, and those with mild, moderate, or severe renal impairment. Each participant receives a single subcutaneous dose of HRS-4729. The study includes 8 participants in each renal impairment group and 8 healthy participants. The effects of the drug are monitored up to approximately 4 weeks after dosing. During the study, participants undergo various assessments including measurement of drug concentration over time Cmax, AUC0-t, AUC0-inf, and secondary measures such as time to maximum concentration, clearance rate, volume of distribution, and half-life. Safety is monitored through vital signs, physical examinations, ECGs, and immunogenicity testing for antibodies against HRS-4729. The total participation duration covers up to about 4 weeks post-dose to evaluate the drugs behavior and safety in different kidney function groups.
CONDITIONS
Brief Title
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
Research Team
Z
Ziwei Du
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here